BSA ؒ IGFBP-3 product correlated closely with peak IGF-I level (r = 0.85; p ! 0.007). Conclusions: Weightbased IGF-I dosing in this cohort resulted in variable IGF-I levels. Considering BSA and serum IGFBP-3 concentration in children is appropriate for subcutaneous IGF-I administration. A combination of these values may yield predictable individualization of rhIGF-I dosing. Open label trial with subcutaneous rhIGF-I (40 g/kg/ dose). Patients studied were children (1 month to 11 years) with diffuse hyperinsulinism (n = 7). Serial serum IGF and insulin-like growth factor binding protein (IGFBP) concentrations were measured by RIA and analyzed by linear Pearson regression. Results: Following the initial rhIGF-I dose, total insulin-like growth factor-I (IGF-I) rose by 56% at 30 min (p ! 0.01) and 85% at 120 min (p ! 0.02). Serum IGF-II, IGFBP-2, and IGFBP-3 levels did not change. Peak serum IGF-I levels within 12 h of the initial rhIGF-I dose were 167-700 mg/ml. The variable peak IGF-I response is attributable in part to IGFBP-3 differences across this pediatric age range. Models of rhIGF-I dosing based upon body surface area (BSA) or initial IGFBP-3 resulted in predictable peak serum IGF-I levels (r = 0.78; p ! 0.03). Recalculating rhIGF-I dosing based upon the
Insulin-like growth factor-I (IGF-I) belongs to the relaxin/insulin family of peptide hormones and exerts major actions in carbohydrate, lipid, and protein metabolism, predominantly through activation of type 1 IGF receptors. Effects of IGFs are modulated by insulin-like growth factor binding proteins (IGFBPs), which are secreted by various cell types and found in most biological fl uids [1] . Over 99% of IGF molecules in human serum circulate in a 150-kDa ternary complex formed by an IGF molecule, IGFBP-3, and the glycoprotein known as the acid-labile subunit (ALS). Recombinant human (rh) IGF-I restores growth and improves insulin action in individuals with growth hormone insensitivity syndrome (GHIS) due to GH receptor mutations, which result in IGF-I defi ciency [2] [3] [4] . Young adults and adolescents with type 1 diabetes have been shown to gain signifi cant benefi ts in glycemic control during recombinant human insulin-like growth factor-I (rhIGF-I) administration [5, 6] . rhIGF-I has been used to promote protein anabolism [7] [8] [9] [10] and to improve insulin sensitivity [11] [12] [13] across diverse clinical conditions, including starvation, AIDSassociated wasting, severe thermal burn, and extreme insulin resistance (type A).
We recently reported the fi rst use of rhIGF-I to suppress insulin oversecretion in children with congenital hyperinsulinism (HI) due to autosomal recessive mutations of the ␤ -cell sulfonylurea receptor ( SUR1 ) [14] .
With the exception of our recent study and use of the related therapeutic IGF-I/IGFBP-3 complex in a burn population [15] , clinical experience with rhIGF-I in the pediatric population has been restricted to patients with GHIS [16] or adolescents with type 1 diabetes mellitus [17, 18] . Children suffering from catabolic burn as well as those with GHIS demonstrate abnormally low serum IGFBP-3 levels. Children with type 1 diabetes may have abnormally low serum IGFBP-3 levels, particularly when metabolic control is poor [19] .
Our study presents the rare opportunity to examine the effects of rhIGF-I dosing in a pediatric population with a wide age span and normal IGFBP-3 levels. According to customary pediatric practice, all children in our trial received rhIGF-I dosed upon their body weight, specifi cally 40 g/kg administered subcutaneously every 12 h. The purpose of this article is to report the effects of weight-based IGF-I dosing across the prepubertal hyperinsulinism patients studied (ages 1 month to 11 years) on IGF axis parameters.
Subjects and Methods

Patient Characteristics and Study Design
The study group was recruited from children with congenital hyperinsulinism, a diagnosis confi rmed by fasting hypoglycemia (serum glucose level ! 50 mg/dl) with concomitant, inadequate suppression of insulin action (insulin 1 2 IU/ml, C-peptide 1 2.2 ng/ ml), in the absence of pituitary or adrenal dysfunction. Children with hyperinsulinism also displayed evidence of increased insulin action when hypoglycemic at the end of a controlled fasting study. Increased insulin action was defi ned as increased glucose utilization, suppressed lipolysis and/or ketogenesis, and/or an inappropriate response to glucagon stimulation (i.e., a rise of serum glucose from baseline by 6 30 mg/dl in response to glucagon 1 mg administered by parenteral or intramuscular injection while hypoglycemic) [20] . Additional entry criterion for this trial was suboptimal glycemic control, defi ned as inability to fast an age-appropriate interval (at least 6 h in infants or 10 h in children), while maintaining serum glucose levels 1 60 mg/dl. Exclusion criteria included suspected insulinoma, history of malignancy, age ! 1 month, hepatic or renal dysfunction, anemia, evidence of intravascular volume depletion, fever, or other evidence of acute infectious disease. The study was approved by the Institutional Review Board. All parents gave written informed consent, and all children 6 8 years gave verbal or written assent. The patients' standard medical care included frequent feedings, diazoxide, octreotide, glucagon, and/or sub-to near-total (95-99%) pancreatectomy [21, 22] . Medical treatments were continued during the study.
Children were admitted to the General Clinical Research Center under an open label protocol in which each child served as his or her control. All received a standard diet. rhIGF-I was administered as 40 g/kg/dose s.c. every 12 h starting at 20: 00 h for a maximum of three doses. Pharmacia & Upjohn Peptide Hormones (now Pfi zer, New York, N.Y., USA) generously provided rhIGF-I. The fi rst IGF-I dose was given before an evening snack and blood was sampled hourly for IGF-I levels for 4 h. The subjects underwent a Sustacal mixed meal tolerance test at 08: 00 h following the second IGF-I dose. When not under study, patients received their usual meals and snacks. Patients received frequent glucose and safety monitoring at all times. Standing height was determined by the mean of triplicate measurements using a wall-mounted stadiometer (Holtain Ltd, UK). Length was determined in infants ! 1 year of age using the mean of triplicate measurements upon a recumbent stadiometer. Body surface area (BSA) was calculated by a modifi cation of the method by Dubois and Dubois [23, 24] .
Height cm Weight kg BSA m 3,600
Assays IGF-I, IGF-II, IGFBP-2, and IGFBP-3 levels were quantifi ed by specifi c RIA (Esoterix Endocrinology, Calabasas Hills, Calif., USA). Prior to IGF RIA, serum samples were extracted with acidethanol to remove IGFBPs. These IGF-I and IGF-II RIAs demonstrate sensitivity of 20 ng/ml and negligibly cross-react with related molecules such as insulin and proinsulin. These IGFBP-2 and IGFBP-3 RIAs possess sensitivity of 5.0 and 0.3 ng/ml, respectively, and do not cross-react with related molecules such as other IGFBPs.
Statistical Analysis
Mean serum IGF and IGFBP levels at baseline (prior to rhIGF-I administration) and during rhIGF-I trial were analyzed by MannWhitney U test (InStat™ for Macintosh ® , version 2.00; GraphPad Software, San Diego, Calif., USA). Basal control values were obtained prior to administration of rhIGF-I to eliminate possible confounding effects of prior exposure to the drug. Peak IGF-I levels were defi ned as the maximal level of IGF-I achieved by 12 h after the initial 40 g/kg dose of rhIGF-I. Pearson linear correlation coeffi cients (r) were calculated to compare relationships between peak IGF-I to body weight, BSA, and levels of each IGFBP. Data are displayed as means 8 SE. All probability values (p) are two-tailed, and values ! 5% were considered signifi cant.
Results
Details of the study group are outlined in table 1 , and genotyping of patients 1-4 has been previously reported [14] . These 4 children were homozygous for the common SUR1 mutations, known to account for approximately 88% of the HI alleles identifi ed in affected Ashkenazi Jewish patients [25] . Patients 5-7 lacked identifi ed SUR1 or Kir6.2 mutations [26] , but were clinically unresponsive to diazoxide, a medication that acts via the SUR1 . Basal serum IGF-I levels were measured at time 0 just prior to administration of the initial 40 g/kg dose of rhIGF-I, administered subcutaneously at time 0, 12 h, and 24 h.
Following the initial rhIGF-I dose, mean serum total IGF-I levels rose rapidly from baseline by 56% at 30 min (p ! 0.01) and by 85% at 120 min ( fi g. 1 A; p ! 0.02) ( fi g. 1 A, table 2 ). Following the initial dose, mean peak serum IGF-I levels were achieved within 2-5 h after the initial dose of rhIGF-I. These peak values were more than double the basal serum IGF-I levels: 373 8 67 vs. 174 8 49 mg/dl (p ! 0.04). [For patient 4, the 12 h value was used in the peak value analysis, as no 2-5 h value was available due to phlebotomy limits.] Peak serum IGF-I Mean serum IGF-II, IGFBP-2, and IGFBP-3 levels did not change signifi cantly during the three-dose rhIGF-I treatment, although serum IGF-II levels trended lower in all subjects and serum IGFBP-3 levels trended higher in most subjects (data not shown). Correlations of peak IGF-I levels with baseline serum IGFBP-2 or IGFBP-3 levels did not reach statistical signifi cance: -0.75 (p ^ 0.053) and +0.65 (p ! 0.08). Fasting serum IGFBP-1 levels in this cohort have been previously reported [14] and did not change signifi cantly on rhIGF-I, consistent with our previous data showing suppression of IGFBP-1 in hyperinsulinism during fasting [27] . The range of peak serum IGF-I levels achieved varied widely across the patient group following the initial weight-based dose: 167-700 ng/ml. All children had received the same dose of rhIGF-I based on body weight regardless of age: 40 g/kg/dose. We modeled the rhIGF-I dose administered based upon BSA, the baseline serum IGFBP-3 level, or the product of BSA and IGFBP-3 level (BSA ؒ IGFBP-3). BSA-based dosing resulted in predictable peak serum IGF-I levels (r = 0.78; p ! 0.03; fi g. 2 A). Dosing based upon the initial serum IGFBP-3 level was equally predictive of peak IGF-I levels as BSA-based dosing (r = 0.78; p ! 0.03; fi g. 2 B). rhIGF-I dosing based upon the BSA ؒ IGFBP-3 product yielded the closest relationship with the highest r value: r = 0.85 (p ! 0.007; fi g. 2 C). Basal serum IGF-I levels were also correlated to BSA and to the BSA ؒ IGFBP-3 product, r = 0.6 and 0.7, respectively.
Discussion
We have presented the effects of prospective rhIGF-I administration in a unique pediatric cohort. In fasting healthy volunteers, rhIGF-I has been shown to lower blood glucose levels through its direct insulin-like action on muscle, liver and other tissues. Decreased serum blood glucose levels result in lower insulin release from pancreatic ␤ -cells. Conversely, prior trials in adults with GHIS [28] [29] [30] as well as in children with GHIS [3] have an associated increase in serum glucose levels during rhIGF-I therapy due to suppression of insulin release. Despite suppression of insulin release by rhIGF-I treatment in our group of children with congenital hyperinsulinism, we observed lack of clinical improvement in fasting tolerance in this trial [14] . This observation may have resulted in part from insulin-like actions caused by the binding of free rhIGF-I to type 1 IGF or hybrid IGF-insulin receptors. Using the conventional dosing regimen for rhIGF-I based on weight alone, we observed unpredictable acute serum IGF-I concentrations in these children ( fi g. 1 ).
Mean peak serum IGF-I levels after a 40 g/kg dose s.c. of rhIGF-I rose at least twofold above basal in our children. Total IGF levels rose rapidly after s.c. administration, while serum IGFBP levels did not change. Thus, serum IGFBP levels and tissue binding sites may have been insuffi cient to buffer against the rapid elevations of the free serum IGF-I levels of these children.
We did not observe signifi cant, acute changes in levels of the major serum IGFBPs (-1, -2 and -3) to account for the unpredictable rise in total IGF-I levels. Serum IGFBP-2 and -3 levels remained within normal ranges, despite supraphysiologic serum IGF-I levels during rhIGF-I administration. Normal developmental differences in basal serum IGFBP-3 concentrations [31] [32] [33] across the age range studied (1 month to 11 years) may have been contributed signifi cantly to the observed variability in IGF pharmacokinetics in our pediatric trial. The lack of change in serum IGFBP-3 levels with acute rhIGF-I treatment in our prepubertal children is consistent with prior trials in children with GHIS [34, 35] or severe insulin resistance [36] . Although only 2 patients in our study received octreotide, which may suppress GH production and hence all GH-related peptides, this commonly used therapy for congenital hyperinsulinism renders less interpretable the changes in serum IGFBP levels observed during rhIGF-I administration to these patients. We included these patients in our analysis because their responses were similar to the other patients and did not alter the data analysis. A larger cohort, if available, would allow comparison of patients with and without octreotide therapy.
Other trials have reported changes in serum IGFBP levels. In patients with complete GHIS, rhIGF-I has been shown to increase serum IGFBP-2 levels [4] . Serum IGFBP-3 levels in type 1 diabetic patients rose after a single, subcutaneous dose of rhIGF-I [37, 38] . In patients with GHIS [39] , chronic rhIGF-I administration has been associated with a drop in serum IGFBP-3 levels. In patients with complete GHIS, rhIGF-I has also been shown to suppress serum IGF-II levels [4] . We did not observe a signifi cant drop in serum IGF-II levels over the 28-hour time course despite a simultaneous rise in free IGF-I levels. rhIGF-I appeared to displace IGF-II from serum IGFBPs, which would likely increase IGF-II clearance.
Euglycemic clamp studies of adults with type 1 diabetes demonstrate that rhIGF-I suppressed overnight GH secretion [20] . Due to phlebotomy limits, we did not assess whether acute suppression of GH occurred in our patients. Of note, octreotide therapy (received by patients 4 and 7) may suppress GH levels.
What is the ideal basis for rhIGF-I dosing in children? The goal of any dosing regimen is to achieve desired therapeutic effects safely and predictably. Factors determining free IGF concentrations include the administered rhIGF-I dose, route of administration, total IGF binding affi nity by serum and tissue IGFBPs, uptake/degradation by tissue IGF receptors, and rates of hepatic, renal, and proteolytic elimination. Several investigators have proposed that bound IGF-I exerts greater biological actions than free IGF-I [40] [41] [42] . Compared to adults, children experience developmental changes in body mass and have increased surface area/volume ratio and relatively smaller intravascular volume [43] . These differences in physiology profoundly affect clinical pharmacology in the pediatric population, and conventional dosing based on weight alone is a rough surrogate for these developmental parameters.
Dosing based on BSA permits more accurate estimation of the volume of distribution. For many drugs, pharmacodynamics based on BSA dosing is superior to weightbased dosing [44] . Total serum IGF-I and IGFBP-3 levels rise with age in normal prepubertal children. The widest pediatric experience with IGF dosing has been seen in patients with complete GHIS or poorly controlled type 1 diabetes. Such patients typically manifest profound perturbations in serum ALS and IGFBP profi les, which in turn affect many rhIGF-I pharmacokinetics [45] . In our trial, in which serum binding proteins signifi cantly regulate free drug bioavailability, and where binding protein concentrations change signifi cantly over time, drug dosing based upon the serum binding protein concentration appears to yield more predictable pharmacokinetics. Others have also suggested that IGFBP-3 levels modulate IGF-I kinetics [46, 47] . In addition, IGF-I treatment in Rabson-Mendalhall syndrome was associated with reduced IGF-I kinetics probably due to low IGFBP-3 [48] .
Infants typically demonstrate low serum ALS levels; perhaps low IGFBP-3 and IGF-I levels are at least as anabolic in infants as in older children with higher ALS, IGFBP-3, and IGF-I levels. We present no data to address the relative, endogenous IGF-I production, but it may be similar when normalized per kilogram of body weight. A lower peak IGF-I level in serum may be suffi cient to support anabolism in the young child, but not in the older child. Our proposed dosing regimen based on BSA and IGFBP-3 may yield similar total IGF-I levels; thus, this regimen may lead to large differences in the biological response. It behooves pediatricians to adjust rhIGF-I dosing by monitoring the serum IGF-I and IGFBP-3 levels to ensure these levels remain in the physiologic ranges, adjusted for age and Tanner stage. We could not address this particular safety issue in the relatively brief time course of this study.
In this trial, BSA and baseline IGFBP-3 concentrations were good predictors of the acute rhIGF-I rise. The BSA ؒ IGFBP-3 product demonstrated the highest r value for predicting rhIGF-I pharmacokinetics. Since rhIGF-I is now under development for a more diverse set of indications, including primary IGF-I defi ciency associated with short stature as well as for hyperglycemic syndromes, dosing and monitoring strategies are essential for the optimization of rhIGF-I therapy. Our fi ndings suggest that a more individualized regimen for initial dosing should consider the baseline IGFBP-3 level. In addition, monitoring serum IGF-I levels and adjusting dose to achieve age-and gender-appropriate IGF-I levels (serum peak and trough) should improve the safety and effi cacy profi les of this emerging new therapeutic modality. The optimal rhIGF-I dose will depend upon the clinical condition being treated and the clinical outcome desired, such as linear growth for GHIS vs. suppression of insulin oversecretion for congenital HI. Figure 2 C provides the simple nomogram for initial rhIGF-I dosing in prepubertal children.
In conclusion, we observed individual variability in IGF-I levels achieved on a weight-based IGF-I dosing regimen in this pediatric cohort with hyperinsulinism, in the absence of acute changes in serum IGFBP or IGF-II levels. Such pharmacokinetic unpredictability underscores the need to tailor drug therapy to each individual child's IGF physiology. This is one of the few trials of rhIGF-I administered to a pediatric population with normal IGFBP-3 levels over a wide age range. Our study supports the concept of BSA alone or in conjunction with baseline serum IGFBP-3 levels as a novel basis for initial rhIGF-I dosing in children. Our pediatric IGF-I dosing model is limited by its short time course and phlebotomy sampling limitations in these young children due to glycemic instability of HI and limited venous access. Future studies should examine the effects of various modes of administration (s.c. vs. i.v.) and compare steady-state free IGF pharmacokinetics with dosing based on anthropometrics and IGFBP-3. Future pharmacokinetic studies during rhIGF-I administration in children should verify the effi cacy of the novel BSA ؒ IGFBP-3-based dosing model while incorporating therapeutic drug monitoring with levels of free IGF-I, IGFBP-3, ALS, and GH in serum.
